GlaxoSmithKline poaches another biotech exec for AI team: 3 notes

Andrea Park - Print  | 

GlaxoSmithKline has hired Kim Branson, PhD, to serve as the British pharmaceutical company's global head of artificial intelligence and machine learning, Bloomberg reports.

Three things to know about the appointment:

1. Dr. Branson previously served as head of AI at Genentech, a San Francisco-based biotech subsidiary of Roche.

2. In his new role, Dr. Branson will reportedly oversee the use of AI to discover novel targets for new drugs, part of GSK's ongoing strategy to speed and improve drug discovery.

3. GSK has a history of recruiting from the Genentech pool: In early 2018, the company hired as its chief scientific officer and president of research and development Hal Barron, MD, who was previously chief medical officer and an executive vice president at Genentech. Other Genentech alums now at GSK include Kevin Sin, head of business development, and Shobie Ramakrishnan, senior vice president of pharma IT.

More articles about AI:
Study: AI outperforms radiologists in managing thyroid nodules
Waystar acquires AI tech firm to streamline prior authorization
Cigna, Celgene join $23M funding round for AI-powered precision healthcare startup

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.